A number of stock research firms have changed their ratings and price targets for Questcor Pharmaceuticals (NASDAQ: QCOR) during the last seven days:
◾Questcor Pharmaceuticals is now covered by analysts at Janney Montgomery Scott. They set a “buy” rating and a $40.00 price target on the stock.
◾Questcor Pharmaceuticals was upgraded by analysts at Mizuho from a “neutral” rating to a “buy” rating. They now have a $41.00 price target on the stock, up previously from $28.00.
◾Questcor Pharmaceuticals was upgraded by analysts at TheStreet from a “hold” rating to a “buy” rating. They wrote, “Questcor Pharmaceuticals (QCOR) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.”
◾Questcor Pharmaceuticals had its price target raised by analysts at Jefferies Group from $30.00 to $38.00. They now have a “buy” rating on the stock. They wrote, “QCOR beat on the topline and EPS on strong Acthar sales despite seasonal MS softness. While mgmt. expects Q1 headwinds including continued MS softness, inventory draw-down and administrative/distribution changes, it reiterated overall Acthar growth with favorable reimbursement outlook.”
◾Questcor Pharmaceuticals had its price target raised by analysts at Ladenburg Thalmann from $33.00 to $38.00. They now have a “buy” rating on the stock.
Merrill had a tentative buy before earnings (insurance and litigation concerns) - as I posted on Max's thread the tone after earnings was completely positive and Price objective moved from $36 to $40. EPS projections went up dramatically for the next three years.
TY Mike, My guess is that both analyst that rated this a hold are now on the buy side and the lowest PT is $38. Well the average just went up considerably. Still the announcements are not hitting the wire.
Sentiment: Strong Buy
Hey, you were the one touting the PhD analysts... I know you are smarter than though. Buy and Sell side analysts, follow them and be a bit late to the party.
But, here are your analyst ratings...
You remind me of BEAR STEARNS,
◾ All analysts were upgrading BSC
◾ Mutual Funds and Institutions and Hedge Funds buying BSC
◾ BSC Bear Stearns Growth Story and low PEG
◾ BSC one of the best breed
◾ BSC making tons of money
◾ BSC overnight from $120 to $2 in 1 week
This is quite a list.
One has to wonder if there will be more today and tomorrow.
Personally if the shorts don't come out smoking today they are going to wish that they had.
Volume will be the key we have to clean out the profit takers here.
Not sure where the shorts are getting all this stock to borrow from but I would hope that soon those lending them shares would pull them as its about time.
They are manipulating buying then smacking the bid, problem is they are buying higher then theey are selling with the accumulation. My guess the stock is presently trading at least $1.50 from where it should have closed due to short selling in a low volume period. There average cost basis is near 33.80. I would not sell now, too much upward side, buy on dips to take away their profits and get PPS over 33.80 to start a small squeeze. And for god sake don't sell to them.
Sentiment: Strong Buy